Breast Cancer Stamp Funds $6.7 Million in 2-Year NCI Grants

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

BETHESDA, Md-Purchasers of the US Postal Service’s breast cancer awareness stamp have funded $6.7 million in 2-year grants to support novel and innovative research into the disease. The National Cancer Institute has given grants to 31 researchers, and a 32nd grant awaits final approval.

BETHESDA, Md—Purchasers of the US Postal Service’s breast cancer awareness stamp have funded $6.7 million in 2-year grants to support novel and innovative research into the disease. The National Cancer Institute has given grants to 31 researchers, and a 32nd grant awaits final approval.

NCI has earmarked its share of money raised by the stamp sales to fund investigators who want to explore areas that are underrepresented in NCI’s research portfolio, particularly high-risk projects that have a potential for a high payoff if successful. One of the aims is to develop new methodologies and technologies that will be seeds for future discovery.

Each grant will provide $75,000 a year for 2 years. NCI expects a number of these projects to develop into mature investigations for which the researchers will seek traditional grant funding.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content